Earnings summaries and quarterly performance for Metagenomi.
Executive leadership at Metagenomi.
Board of directors at Metagenomi.
Research analysts covering Metagenomi.
Recent press releases and 8-K filings for MGX.
Metagenomi Provides Update on MGX-001 Program and Financial Runway
MGX
New Projects/Investments
Guidance Update
- Metagenomi, an in vivo genome editing company, is advancing its lead program, MGX-001 for hemophilia A, towards clinical development, with a pre-IND meeting with the FDA planned for later this year (2025) and an IND/CTA filing in Q4 2026.
- Preclinical data for MGX-001 demonstrated curative factor VIII activity and dose-dependent efficacy in non-human primates, with durability observed for up to 19 months.
- The company's cash runway is anticipated to extend into Q4 2027.
- Metagenomi is also progressing programs in cardiometabolic indications through a partnership with Ionis, with plans to announce additional targets and development candidates later this year (2025).
Nov 20, 2025, 9:30 AM
Metagenomi Updates on MGX001 Program and Pipeline at Jefferies 2025 Global Healthcare Conference
MGX
New Projects/Investments
Guidance Update
- Metagenomi's lead program, MGX001 for hemophilia A, demonstrated curative factor VIII activity and dose-dependent efficacy in non-human primates, with durability up to 19 months and no identifiable off-target editing.
- The company is on track for a pre-IND meeting with the FDA later this year (2025) and plans to file an IND/CTA in Q4 2026 for MGX001, with clinical trials initiating in 2027.
- Metagenomi anticipates its cash runway will extend into Q4 2027.
- Through a partnership with Ionis Pharmaceuticals, Metagenomi is progressing programs in cardiometabolic indications, including TTR and AGT, and expects to announce additional targets and a first development candidate later this year (2025).
Nov 20, 2025, 9:30 AM
Metagenomi Provides Update on Lead Program MGX001 and Financial Outlook
MGX
Guidance Update
New Projects/Investments
- Metagenomi anticipates its cash runway into Q4 2027.
- The company's lead program, MGX001 for hemophilia A, is on track for a pre-IND meeting with the FDA later this year and an IND CTA filing in Q4 2026.
- Preclinical data for MGX001 demonstrated curative factor VIII activity and dose-dependent efficacy in non-human primates, with durable expression over 19 months and no identifiable off-target editing.
- Metagenomi is collaborating with Ionis Pharmaceuticals on cardiometabolic indications, with plans to announce additional targets and development candidates later this year.
Nov 20, 2025, 9:30 AM
Metagenomi Announces Strategic Pipeline Prioritization, Workforce Reduction, and Leadership Changes
MGX
Earnings
CEO Change
Layoffs
- Metagenomi reported $184.1 million in cash, cash equivalents, and available-for-sale marketable securities as of September 30, 2025, which is anticipated to extend its cash runway into the fourth quarter of 2027.
- The company announced a strategic pipeline prioritization, focusing on its wholly-owned MGX-001 hemophilia A program, which demonstrated curative FVIII activity in non-human primates, with IND/CTA submissions expected in 4Q 2026. This strategy included deprioritizing early discovery and platform research.
- An organizational restructuring resulted in a 25% workforce reduction, contributing to the extended cash runway.
- Jian Irish, Ph.D., M.B.A., was appointed Chief Executive Officer, succeeding Brian Thomas, Ph.D., who will remain on the Board of Directors, and Dr. Willard Dere was named the new Board Chair.
Nov 12, 2025, 1:39 PM
Ask Fintool AI Agent
Get instant answers from SEC filings, earnings calls & more